PDCD1 and neoplasm: Inhibitors targeting these checkpoints aim to disrupt the interaction between PD-1 and PD-L1, thereby preserving the anti-tumor properties of T cells, reversing immune evasion, and restoring their capacity to induce tumor cell death.